Source: 헬스코리아뉴스(http://www.hkn24.com)
← 返回列表CompanyIn April of last year, 翰林制药 signed a 联合研发 and investment agreement with emerging 生物风投企业 RudaCure for the 干眼症治疗药 'RCI001.' According to the company's announcement at the time, 'RCI001' showed faster promotion of 泪液分泎 and 角膜损伤恢复 compared to commercially available competing drugs, along with superior 滴眼顺应性 and safety. Through a mechanism that suppresses 炎症激活, it exerts powerful 抗炎和抗氧化效果 to alleviate 干眼症.
Source: 헬스코리아뉴스(http://www.hkn24.com) ← 返回列表
制药企业纷纷挑战干眼症治疗药开发
2021-12-30
Source: 헬스코리아뉴스(http://www.hkn24.com)